Real-life experience of Fluocinolone Acetonide Implant (Iluvien®) in non-infectious uveitic macular edema
Purpose
To evaluate the efficacy and safety of the Fluocinolone Acetonide (FAc, Iluvien) implant in uveitic macular edema (UME).
Methods
Retrospective, multicenter (France) real-life study including patients with UME and having received at least 1 FAc injection.
Results
26 eyes of 23 patients (mean age:60+/-16 years) were included with a mean follow-up of 10.4+/-6.6 months. Uveitis was anterior, intermediate, posterior/panuveitis in 0%,12% and 88% of cases. All eyes received at least 1 Dexamethasone injection (DEXi) prior to FAc with an average of 1.5 DEXi/year. Before FAc, 27% of patients were on oral steroids and 27% on immunosuppressants. 25 eyes were pseudophakic. The mean best corrected visual acuity (BCVA) was 0.43+/-0.36 LogMAR at baseline increasing to 0.32+/-0.45 at 1 month (M1), 0.21+/-0.27 at M3, 0.21+/-0.27 at M6 and 0.31+/-0.31 at M12 (all p<0.05).The mean baseline central macular thickness (CMT) was 400+/-110µm decreasing to 307+/-65 at M1, 313+/-94 at M3, 329+/-94 at M6 and 307+/-53µm at M12 (all p<0.05). UME was absent in 84%, 84%, 78% and 64% at M1, 3, 6 and 12. Four eyes experienced a relapse of UME (5+/-2.4 months after FAc) requiring a new DEXi. The mean number of DEXi decreased to 0.20/year after FAc. At the last follow-up, 42% of patients had reduced their dose of oral steroids. No immunosuppressive treatment could be stopped. Five eyes (19%) showed ocular hypertension requiring anti-glaucoma drops (but no surgery). One eye was transiently hypotonic. No other adverse events were noted.
Conclusion
The FAc implant led to a significant improvement in BCVA and CMT up to 12 months. The majority of adverse events were mild and controlled by medical treatment.
Conflict of interest
No
Authors 1
Last name
TOUHAMI
Initials of first name(s)
S
Department
Ophthalmology
City
Paris
Country
France
Authors 2
Last name
Jabbour
Initials of first name(s)
M
Department
Ophthalmology
City
Paris
Country
France
Authors 3
Last name
Rougier
Initials of first name(s)
MB
Department
Ophthalmology
City
Bordeaux
Country
France
Authors 4
Last name
Serrar
Initials of first name(s)
Y
Department
Ophthalmology
City
Lyon
Country
France
Authors 5
Last name
Kodjikian
Initials of first name(s)
L
Department
Ophthalmology
City
Lyon
Country
France
Authors 6
Last name
Mazhar
Initials of first name(s)
D
Department
Ophthalmology
City
Nantes
Country
France
Authors 7
Last name
Weber
Initials of first name(s)
M
Department
Ophthalmology
City
Nantes
Country
France
Authors 8
Last name
Perez-Roustit
Initials of first name(s)
S
Department
Ophthalmology
City
Grenoble
Country
France
Authors 9
Last name
Chiquet
Initials of first name(s)
C
Department
Ophthalmology
City
Grenoble
Country
France
Authors 10
Last name
Bodaghi
Initials of first name(s)
B
Department
Ophthalmology
City
Paris
Country
France
This website uses cookies to ensure you get the best experience on our website.
Learn more